Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
AAAS Resources on Open Access aaas.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aaas.org Daily Mail and Mail on Sunday newspapers.
Clinical stage generative artificial intelligence (AI)-driven biotechnology company InSilico Medicine ("InSilico"), today announced that the Journal of Medicinal Chemistry, an ACS Publications journal focusing on critical studies about molecular structure and biological activity, has published the company's discovery of a novel PHD inhibitor for the treatment of anemia.
Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising new therapeutic target for breast and gynecological cancer, and discovered a series of novel, potent, and highly selective inhibitors specifically targeting MYT1.